Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25945375 | 0.90 | FFAR1 (0.42) | UCHL1FFAR1 | |
| SCHEMBL30200601 | 0.87 | FFAR1 (0.43) | UCHL1FFAR1 | |
| SCHEMBL1359697 | 0.84 | FFAR1 (0.55) | UCHL1FFAR1 | |
| SCHEMBL18125399 | 0.81 | UCHL1 (0.45) | UCHL1FFAR1CYP1A2 | |
| SCHEMBL21266730 | 0.81 | UCHL1 (0.38) | UCHL1FFAR1 | |
| SCHEMBL18570334 | 0.81 | UCHL1 (0.39) | UCHL1FFAR1 | |
| SCHEMBL30201150 | 0.79 | UCHL1 (0.41) | UCHL1FFAR1 | |
| SCHEMBL16402984 | 0.79 | FFAR1 (0.40) | UCHL1FFAR1 | |
| SCHEMBL18570335 | 0.79 | UCHL1 (0.40) | UCHL1FFAR1 | |
| SCHEMBL21266884 | 0.78 | UCHL1 (0.43) | UCHL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746964-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026046976-A1 | PYRAZOLOPYRIDINE PHOSPHATE ESTERS FOR MODULATING SALT-INDUCIBLE KINASE (SIK) | F. HOFFMANN-LA ROCHE AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| EP-4642535-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642773-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025017078-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024141443-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141444-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | UCHL1 3195/4885FFAR1 1981/4885CYP17A1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.